What Is DILIN?
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has established the Drug-Induced Liver Injury Network (DILIN) to collect and analyze cases of severe liver injury caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements. Currently, DILIN is conducting 2 registry studies:
- Retrospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 10 years after using any of 7 specific drugs and one drug category (quinolone antibiotics).
- Prospective Study, to establish a nationwide registry of people who have experienced liver injury within the past 6 months after using certain drugs or alternative products.
- Causality Process and Web Application, The diagnosis of drug-induced liver injury relies on evidence linking the injury to a specific drug or agent. DILIN uses “expert opinion” to determine the degree of association between the implicated medication(s) and the liver injury. This process is identified as DiLiN Causality Case Adjudication which is the DiLiN project primary Endpoint. The DiLiN Causality Web Application is a system specifically developed for this purpose. This is a secure system which was developed by the DCRI IT group for the DILIN network based on an open source platform. The Causality Web Application’s mission is to streamline the previous process which will include more efficient case management and seamless system integration to existing DILIN databases. The DiLiN Causality Web Application is also providing greater consistency within the processes by applying business rules to user’s input.
Interested in participating in this study? Contact Us
Late Breaking News: